New targeting strategies in drug therapy of inflammatory bowel disease: Mechanistic approaches and opportunities

Expert Opinion on Drug Delivery

Volumn 10, Issue 9, 2013, Pages 1275-1286

  Wolk, Omri ^a   Epstein, Svetlana ^a   Ioffe Dahan, Viktoriya ^a   Ben Shabat, Shimon ^a   Dahan, Arik ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Anti inflammatory peptides; Antibodies; Crohn's disease; Drug delivery targeting; Gene therapy delivery; Inflammatory bowel disease; JAK inhibitors; Particulate systems; Tofacitinib; Transgenic bacteria; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZO REDUCTASE; BALSALAZIDE; BECLOMETASONE; BUDESONIDE; CERTOLIZUMAB PEGOL; CYCLODEXTRIN; ECABET; ENEMA; GHRELIN; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; JANUS KINASE INHIBITOR; MELATONIN; NATALIZUMAB; NICOTINE; OLSALAZINE; PEPTIDE TRANSPORTER 1; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; STEROID; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB;

ACTIVE IMMUNIZATION; ANTIINFLAMMATORY ACTIVITY; APICAL MEMBRANE; BIOACCUMULATION; CHEMICAL MODIFICATION; COLON FLORA; CROHN DISEASE; DESCENDING COLON; DISEASE MARKER; DOG; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; ESCHERICHIA COLI; FIRST PASS EFFECT; GENETIC ENGINEERING; HOSPITALIZATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE INJURY; INTESTINE PERFUSION; INTESTINE PRESSURE; JC VIRUS; LACTOCOCCUS LACTIS; MATERIAL COATING; NEUTROPHIL COUNT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PATIENT COMPLIANCE; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENT INFECTION; RETICULOENDOTHELIAL SYSTEM; REVIEW; SURFACE CHARGE; T LYMPHOCYTE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL AGENTS; GENETIC THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 84882406042     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.800480     Document Type: Review

References (147)

1. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000;47(3):410-14
2. Rhodes JM, Robinson R, Beales I, et al. Clinical trial: Oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther 2008;27(3):228-40
3. Malaty HM, Fan X, Opekun AR, et al. Rising incidence of inflammatory bowel disease among children: A 12-year study. J Pediatr Gastroenterol Nutr 2010;50(1):27-31
4. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends. Inflamm Bowel Dis 2011;17(1):423-39
5. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003- 2005: A population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101(6):1274-82 (Pubitemid 43833122)
6. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44(2):265-7 (Pubitemid 46175082)
7. Dahan A, Amidon GL, Zimmermann EM. Drug targeting strategies for the treatment of inflammatory bowel disease: A mechanistic update. Expert Rev Clin Immunol 2010;6(4):543-50
8. Kesisoglou F, Zimmermann EM. Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin Drug Deliv 2005;2(3):451-63 (Pubitemid 41683221)
9. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361(21):2066-78
10. Gionchetti P, Rizzello F, Morselli C, Campieri M. Review article: Problematic proctitis and distal colitis. Aliment Pharmacol Ther 2004;20(Suppl 4):93-6 (Pubitemid 39319255)
11. Frei P, Biedermann L, Manser CN, et al. Topical therapies in inflammatory bowel disease. Digestion 2012;86(Suppl 1):36-44
12. Lawrance IC. Novel topical therapies for distal colitis. World J Gastrointest Pharmacol Ther 2010;1(5):87-93
13. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: The role in distal ulcerative colitis. Am J Gastroenterol 2000;95(7):1628-36 (Pubitemid 30484995)
14. Kagan L, Hoffman A. Systems for region selective drug delivery in the gastrointestinal tract: Biopharmaceutical considerations. Expert Opin Drug Deliv 2008;5(6):681-92 (Pubitemid 351998257)
15. Pinto JF. Site-specific drug delivery systems within the gastro-intestinal tract: From the mouth to the colon. Int J Pharm 2010;395(1-2):44-52
16. Van den Mooter G. Colon drug delivery. Expert Opin Drug Deliv 2006;3(1):111-25
17. Dahan A, Khamis M, Agbaria R, Karaman R. Targeted prodrugs in oral drug delivery: The modern molecular biopharmaceutical approach. Expert Opin Drug Deliv 2012;9(8):1001-13
18. Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2000;2(1):E6
19. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003;6(1):33-66 (Pubitemid 37207241)
20. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos 1990;11(6):465-75 (Pubitemid 20271436)
21. Dahan A, Amidon GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 2009;297(2):G371-7
22. Dahan A, Amidon GL. MRP2 mediated drug-drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm 2010;386(1-2):216-20
23. Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 2005;57(2):303-16 (Pubitemid 39536104)
24. Hofer KN. Oral budesonide in the management of Crohn's disease. Ann Pharmacother 2003;37(10):1457-64 (Pubitemid 37205505)
25. Basit AW, Short MD, McConnell EL. Microbiota-triggered colonic delivery: Robustness of the polysaccharide approach in the fed state in man. J Drug Target 2009;17(1):64-71
26. Chourasia MK, Jain SK. Polysaccharides for colon targeted drug delivery. Drug Deliv 2004;11(2):129-48 (Pubitemid 38437082)
27. Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 2010;7(5):1388-405
28. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001;48(4):571-7 (Pubitemid 32234805)
29. Krishnamachari Y, Madan P, Lin S. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm 2007;338(1-2):238-47 (Pubitemid 46777247)
30. Bartil T, et al. Swelling behavior and release properties of pH-sensitive hydrogels based on methacrylic derivatives. Acta Pharm 2007;57(3):301-14 (Pubitemid 47429180)
31. Sandborn WJ, Hanauer SB. Systematic review: The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17(1):29-42 (Pubitemid 36140432)
32. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995;16(5):351-80
33. McConville JT, Ross AC, Florence AJ, Stevens HN. Erosion characteristics of an erodible tablet incorporated in a time-delayed capsule device. Drug Dev Ind Pharm 2005;31(1):79-89 (Pubitemid 40170589)
34. Stevens HN, Wilson CG, Welling PG, et al. Evaluation of pulsincap to provide regional delivery of dofetilide to the human GI tract. Int J Pharm 2002;236(1-2):27-34 (Pubitemid 34219370)
35. Hu Z, Mawatari S, Shimokawa T, et al. Colon delivery efficiencies of intestinal pressure-controlled colon delivery capsules prepared by a coating machine in human subjects. J Pharm Pharmacol 2000;52(10):1187-93
36. Shibata N, Ohno T, Shimokawa T, et al. Application of pressure-controlled colon delivery capsule to oral administration of glycyrrhizin in dogs. J Pharm Pharmacol 2001;53(4):441-7 (Pubitemid 32396534)
37. Bassotti G, Gaburri M. Manometric investigation of high-amplitude propagated contractile activity of the human colon. Am J Physiol 1988;255(5 Pt 1):G660-4
38. Hu Z, Kimura G, Mawatari S, et al. New preparation method of intestinal pressure-controlled colon delivery capsules by coating machine and evaluation in beagle dogs. J Control Release 1998;56(1-3):293-302 (Pubitemid 28511149)
39. Hu Z, Kimura G, Ito Y, et al. Technology to obtain sustained release characteristics of drugs after delivered to the colon. J Drug Target 1999;6(6):439-48 (Pubitemid 29452687)
40. Rao SS, Sadeghi P, Beaty J, et al. Ambulatory 24-h colonic manometry in healthy humans. Am J Physiol Gastrointest Liver Physiol 2001;280(4):G629-39
41. Nanda K, Moss AC. Update on the management of ulcerative colitis: Treatment and maintenance approaches focused on MMX((R)) mesalamine. Clin Pharmacol 2012;4:41-50
42. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: Results from the CORE I study. Gastroenterology 2012;143(5):1218-26; e1-2
43. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132(1):66-75; quiz 432-3 (Pubitemid 46108735)
44. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: New approaches and in vitro/in vivo evaluation. Int J Pharm 2002;235(1-2):1-15 (Pubitemid 34185432)
45. Katsuma M, Watanabe S, Takemura S, et al. Scintigraphic evaluation of a novel colon-targeted delivery system (CODES) in healthy volunteers. J Pharm Sci 2004;93(5):1287-99 (Pubitemid 38529702)
46. Varshosaz J, Emami J, Tavakoli N, et al. Development of novel budesonide pellets based on CODES(TM) technology: In vitro/in vivo evaluation in induced colitis in rats. Daru 2011;19(2):107-17
47. Bosani M, Ardizzone S, Porro G. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 2009;3:77-97
48. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3(7):521-33 (Pubitemid 37328672)
49. Chu WM. Tumor necrosis factor. Cancer Lett 2013;328(2):222-5
50. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93(11):2645-68 (Pubitemid 39506617)
51. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128(4):862-9 (Pubitemid 40523539)
52. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350(9):876-85 (Pubitemid 38252535)
53. Shteyer E, Wilschanski M. Novel therapeutic modalities in pediatric inflammatory bowel disease. Isr Med Assoc J 2008;10(11):816-20
54. Sands BE, Blank MA, Patel K, van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn's disease: Response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2(10):912-20 (Pubitemid 39335798)
55. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):644-59; quiz 660
56. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with Inflammatory Bowel Disease (IBD): A meta-analysis. Am J Gastroenterol 2013;108(1):40-7
57. Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013;12(7):703-8
58. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133(1):312-39 (Pubitemid 47031141)
59. Kestens C, van Oijen MG, Mulder CL, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol 2013; in-press
60. Molander P, Sipponen T, Kemppainen H, et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha-blocking agents in IBD. J Crohns Colitis 2012;S1873-9946(12):00455-2
61. Semerano L, Assier E, Delavallee L, Boissier MC. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin Biol Ther 2011;11(4):545-50
62. Perrier C, Rutgeerts P. New drug therapies on the horizon for IBD. Dig Dis 2012;30(Suppl 1):100-5
63. Delavallee L, Semerano L, Assier E, et al. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: A long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009;11(6):R195
64. Iwakura Y, Ishigame H. The IL-23/IL- 17 axis in inflammation. J Clin Invest 2006;116(5):1218-22
65. Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn's disease: Pathogenetic relevance and therapeutic implication. World J Gastroenterol 2006;12(35):5606-10 (Pubitemid 44594033)
66. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/ 23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135(4):1130-41
67. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367(16):1519-28
68. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348(1):24-32 (Pubitemid 36026343)
69. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25 (Pubitemid 41565956)
70. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology 2007;132(5):1672-83 (Pubitemid 46695722)
71. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353(4):369-74 (Pubitemid 41132341)
72. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353(4):375-81 (Pubitemid 41132342)
73. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352(24):2499-507 (Pubitemid 41007865)
74. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6(12):1370-7
75. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18(8):1470-9
76. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 2012; Epub ahead of print
77. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: A randomised study. Gut 2011;60(8):1068-75
78. Kontzias A, Kotlyar A, Laurence A, et al. Jakinibs: A new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 2012;12(4):464-70
79. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367(7):616-24
80. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60(7):1895-905
81. Gassler N, Rohr C, Schneider A, et al. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol 2001;281(1):G216-28
82. McGuckin MA, Eri R, Simms LA, et al. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009;15(1):100-13
83. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008;14(3):401-7 (Pubitemid 351320848)
84. Edelblum KL, Turner Jr. The tight junction in inflammatory disease: Communication breakdown. Curr Opin Pharmacol 2009;9(6):715-20
85. Hisamatsu T, Kanai T, Mikami Y, et al. Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol Ther 2013;137(3):283-97
86. Nakase H, Okazaki K, Tabata Y, Chiba T. Biodegradable microspheres targeting mucosal immune-regulating cells: New approach for treatment of inflammatory bowel disease. J Gastroenterol 2003;38(Suppl 15):59-62 (Pubitemid 36442889)
87. Serra L, Domenech J, Peppas NA. Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. Eur J Pharm Biopharm 2009;71(3):519-28
88. Meissner Y, Lamprecht A. Alternative drug delivery approaches for the therapy of inflammatory bowel disease. J Pharm Sci 2008;97(8):2878-91
89. Boltin D, Perets TT, Vilkin A, Niv Y. Mucin function in inflammatory bowel disease: An update. J Clin Gastroenterol 2013;47(2):106-11
90. Collnot EM, Ali H, Lehr CM. Nanoand microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release 2012;161(2):235-46
91. Onishi H, Oosegi T, Machida Y. Efficacy and toxicity of Eudragit-coated chitosan-succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis. Int J Pharm 2008;358(1-2):296-302
92. Mura C, Nacher A, Merino V, et al. N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: In vivo study with TNBS-induced colitis model in rats. Int J Pharm 2011;416(1):145-54
93. Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther 2008;15(17):1200-9
94. Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of microand nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 2001;18(6):788-93 (Pubitemid 32783514)
95. Lamprecht A, Ubrich N, Yamamoto H, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001;299(2):775-81
96. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 2005;315(1):196-202 (Pubitemid 41380512)
97. Makhlof A, Tozuka Y, Takeuchi H. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm 2009;72(1):1-8
98. Tahara K, Samura S, Tsuji K, et al. Oral nuclear factor-kappaB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide- coglycolide) nanospheres for inflammatory bowel disease. Biomaterials 2011;32(3):870-8
99. Gabor F, Bogner E, Weissenboeck A, Wirth M. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev 2004;56(4):459-80 (Pubitemid 38210417)
100. Wang XY, Koller R, Wirth M, Gabor F. Lectin-coated PLGA microparticles: Thermoresponsive release and in vitro evidence for enhanced cell interaction. Int J Pharm 2012;436(1-2):738-43
101. Bies C, Lehr CM, Woodley JF. Lectin-mediated drug targeting: History and applications. Adv Drug Deliv Rev 2004;56(4):425-35 (Pubitemid 38210415)
102. Sakhalkar HS, Hanes J, Fu J, et al. Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules. FASEB J 2005;19(7):792-4 (Pubitemid 40617386)
103. Sakhalkar HS, Dalal MK, Salem AK, et al. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc Natl Acad Sci USA 2003;100(26):15895-900 (Pubitemid 38021086)
104. Laroui H, Sitaraman SV, Merlin D. Gastrointestinal delivery of anti-inflammatory nanoparticles. Methods Enzymol 2012;509:101-25
105. Parodi A, Quattrocchi N, van de Ven AL, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 2013;8(1):61-8
106. Jubeh TT, Antler S, Haupt S, et al. Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. Mol Pharm 2005;2(1):2-11 (Pubitemid 40314724)
107. Kesisoglou F, Zhou SY, Niemiec S, et al. Liposomal formulations of inflammatory bowel disease drugs: Local versus systemic drug delivery in a rat model. Pharm Res 2005;22(8):1320-30 (Pubitemid 41176036)
108. Jubeh TT, Barenholz Y, Rubinstein A. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm Res 2004;21(3):447-53 (Pubitemid 38338980)
109. Jubeh TT, Nadler-Milbauer M, Barenholz Y, et al. Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. J Drug Target 2006;14(3):155-63 (Pubitemid 43878824)
110. Tirosh B, Khatib N, Barenholz Y, et al. Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol Pharm 2009;6(4):1083-91
111. Bhol KC, Schechter PJ. Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis. Dig Dis Sci 2007;52(10):2732-42 (Pubitemid 47373915)
112. Motilva V, Talero E, Calvo JR, et al. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities. Curr Pharm Des 2008;14(1):71-95 (Pubitemid 351266986)
113. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134(1):166-78 (Pubitemid 350309324)
114. Ingersoll SA, Ayyadurai S, Charania MA, et al. The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2012;302(5):G484-92
115. Adibi SA. Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. Am J Physiol Gastrointest Liver Physiol 2003;285(5):G779-88 (Pubitemid 37310056)
116. Merlin D, Si-Tahar M, Sitaraman SV, et al. Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease: Transport of bacterial peptides influences expression of MHC class 1 molecules. Gastroenterology 2001;120(7):1666-79 (Pubitemid 32523485)
117. Bettenworth D, Buyse M, B€ohm M, et al. The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function. Am J Pathol 2011;179(3):1230-42
118. Abad C, Martinez C, Juarranz MG, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003;124(4):961-71 (Pubitemid 36389799)
119. Cuzzocrea S, Mazzon E, Serraino I, et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 2001;30(1):1-12 (Pubitemid 32056605)
120. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 2006;130(6):1707-20 (Pubitemid 43668852)
121. Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010;138(3):843-53; e1-2
122. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis 2011;17(3):831-48
123. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011;140(6):1704-12
124. Kim DJ, Kim KS, Song MY, et al. Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa. Clin Immunol 2012;144(3):190-9
125. Arsenescu V, Narasimhan ML, Halide T, et al. Adiponectin and plant-derived mammalian adiponectin homolog exert a protective effect in murine colitis. Dig Dis Sci 2011;56(10):2818-32
126. Elinav E, Adam N, Waks T, Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology 2009;136(5):1721-31
127. Matsumoto H, Kimura T, Haga K, et al. Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors. BMC Gastroenterol 2010;10:44
128. Polyak S, Mah C, Porvasnik S, et al. Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5. Dig Dis Sci 2008;53(5):1261-70 (Pubitemid 351514644)
129. Polyak S, Mach A, Porvasnik S, et al. Identification of adeno-associated viral vectors suitable for intestinal gene delivery and modulation of experimental colitis. Am J Physiol Gastrointest Liver Physiol 2012;302(3):G296-308
130. Kriegel C, Amiji M. Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release 2011;150(1):77-86
131. Felgner PL, Gadek TR, Holm M, et al. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84(21):7413-17
132. Dinser R, Kreppel F, Zaucke F, et al. Comparison of long-term transgene expression after non-viral and adenoviral gene transfer into primary articular chondrocytes. Histochem Cell Biol 2001;116(1):69-77 (Pubitemid 32695820)
133. Hama S, Akita H, Ito R, et al. Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems. Mol Ther 2006;13(4):786-94
134. Wirtz S, Neurath MF. Gene transfer approaches for the treatment of inflammatory bowel disease. Gene Ther 2003;10(10):854-60 (Pubitemid 36656630)
135. Plevy S.E, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology 2011;140(6):1838-46
136. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 2013;29(2):184-9
137. Rolfe VE, Fortun PJ, Hawkey CJ, et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006(4):CD004826
138. Naidoo K, Gordon M, Fagbemi AO, et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011(12):CD007443
139. Sartor RB. Efficacy of probiotics for the management of inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2011;7(9):606-8
140. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289(5483):1352-5 (Pubitemid 30656052)
141. Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003;21(7):785-9 (Pubitemid 36791397)
142. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4(6):754-9 (Pubitemid 43841860)
143. Wells J. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annu Rev Food Sci Technol 2011;2:423-45
144. Vandenbroucke K, Hans W, Van Huysse J, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004;127(2):502-13 (Pubitemid 39091899)
145. Vandenbroucke K, de Haard H, Beirnaert E, et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2010;3(1):49-56
146. Foligne B, Dessein R, Marceau M, et al. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 2007;133(3):862-74 (Pubitemid 47374132)
147. Westendorf AM, Gunzer F, Deppenmeier S, et al. Intestinal immunity of Escherichia coli NISSLE 1917: A safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 2005;43(3):373-84 (Pubitemid 40228949)